In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 427-432

  Akizawa, Hiromichi ^a   Zhao, Songji ^b   Takahashi, Masayuki ^a   Nishijima, Ken ichi ^b   Kuge, Yuji ^b,c   Tamaki, Nagara ^b,c   Seki, Koh ichi ^c   Ohkura, Kazue ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

125I IIMU; Angiogenic enzyme imaging; Thymidine phosphorylase

Indexed keywords

5 IODO 6 [(2 IMINOIMIDAZOLIDINYL)METHYL]URACIL I 125; THYMIDINE PHOSPHORYLASE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE RADIOISOTOPES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; URACIL;

EID: 77952549668     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.01.005     Document Type: Article

References (24)

1. Takebayashi Y., Yamada K., Miyadera K., Sumizawa T., Furukawa T., Kinoshita F., et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 1996, 32A:1227-1232.
2. Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., et al. Angiogenic factor. Nature 1992, 356:668.
3. Haraguchi M., Miyadera K., Uemura K., Sumizawa T., Furukawa T., Yamada K., et al. Angiogenetic activity of enzymes. Nature 1994, 368:198.
4. Tanaka Y., Kobayashi H., Suzuki M., Kanayama N., Suzuki M., Terao T. Thymidine phosophorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum Pathol 2002, 33:1105-1113.
5. O'Brien T., Granston D., Fuggle S., Biknell R., Harris A.L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995, 55:510-513.
6. Shimaoka S., Matsushita S., Nitanda T., Matsuda A., Nioh T., Suenaga T., et al. The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer 2000, 88:2220-2227.
7. Fujimoto J., Sakaguchi H., Hirose R., Wen H., Tamaya T. Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Cancer Res 1999, 59:3041-3044.
8. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase in human colorectal carcinoma. J Natl Cancer Inst 1996, 88:1100-1107.
9. Imazano Y., Takebayashi Y., Nishiyama K., Akiba S., Miyadera K., Yamada Y., et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997, 15:2570-2578.
10. Cole C., Foster A.J., Freeman S., Jaffar M., Murray P.E., Stratford I.J. The role of thymidine phosphorylase/PD-ECGF in cancer chemotherapy; a chemical perspective. Anticancer Drug Des 1999, 14:383-392.
11. Kono A., Hara Y., Matsushita Y. Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)-5-fluorouracil in human tumor tissues. Chem Pharm Bull (Tokyo) 1981, 29:1486-1488.
12. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosophorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58:685-690.
13. Dexter D.L., Wolberg W.H., Ansfield F.J., Helson L., Heidelberger C. The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res 1972, 32:247-253.
14. Klecker R.W., Collins J.M. Thymidine phosphorylase as a target for imaging and therapy with thymine analogs. Cancer Chemother Pharmacol 2001, 48:407-412.
15. 18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004, 31:1033-1041.
16. Grierson J.R., Brockenbrough J.S., Rasey J.S., Wiens L.W., Schwartz J.L., Jordan R., et al. Evaluation of 5'-deoxy-5'-[F-18]fluorothymidine as a tracer of intracellular thymidine phosphorylase activity. Nucl Med Biol 2007, 34:471-478.
17. Yano S., Kazuno H., Sato T., Suzuki N., Emura T., Wierzba K., et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives: Part 2. Optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase. Bioorg Med Chem 2004, 12:3443-3450.
18. 11C-labeled uracil derivative for a PET tracer targeting thymidine phosphorylase. Heterocycles 2008, 76:237-241.
19. Takahashi M., Seki K., Nishijima K., Zhao S., Kuge Y., Tamaki N., et al. Synthesis of a radioiodinated thymidine phosphorylase inhibitor and its preliminary evaluation as a potential SPECT tracer for angiogenic enzyme expression. J Label Compd Radiopharm 2008, 51:384-387.
20. 125I]iodouracil as a potential thymidine phosphorylase-targeted radiopharmaceutical: synthesis and preliminary biological evaluation. J Label Compd Radiopharm 2009, 52:146-150.
21. Shirasaka T., Nagayama S., Kitano S., Maehara Y., Fujii S. Pyrimidine nucleoside phosphorylase in rodents and human. Gan To Kagaku Ryoho 1981, 8:262-269.
22. Bruin M.D., Capel T.V., Bom K.V.D., Kruyt F.A., Fukushima M., Hoekman K., et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003, 88:957-964.
23. 18F-2-Deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991, 67:1544-1550.
24. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004, 45:695-700.